MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
2.450
-0.050
-2.00%
Opening 09:38 07/09 EDT
OPEN
2.490
PREV CLOSE
2.500
HIGH
2.500
LOW
2.450
VOLUME
13.98K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
0.9657
MARKET CAP
11.76M
P/E (TTM)
-0.3501
1D
5D
1M
3M
1Y
5Y
1D
Phio Pharmaceuticals Announces 2025 Annual Meeting Details
TipRanks · 1d ago
Weekly Report: what happened at PHIO last week (0630-0704)?
Weekly Report · 2d ago
Weekly Report: what happened at PHIO last week (0623-0627)?
Weekly Report · 06/30 10:07
Phio Pharmaceuticals Advances in PH-762 Clinical Trial
TipRanks · 06/26 10:30
Phio Pharmaceuticals Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 06/25 14:54
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
Benzinga · 06/25 14:43
Phio Pharmaceuticals’ PH-762: Promising Clinical Progress and Strategic Potential Drive Buy Rating
TipRanks · 06/25 13:35
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Newsfile · 06/25 11:45
More
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Webull offers Phio Pharmaceuticals Corp stock information, including NASDAQ: PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.